Medicines/Products by Categories


UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED 31ST DECEMBER, 2003
(RS. IN LACS)
PARTICULARS
For the quarter ended 31.12.2003 (Provisional)
For the quarter ended 31.12.2002
(Provisional)
For theNine months ended 31.12.2003 (Provisional)
For the Nine months ended 31.12.2002
(Provisional)
For the year ended 31.03.2003 (Audited)
SALES
5334.33
4632.12
15398.91
13540.27
17828.63
Others Income
42.67
29.79
63.11
63.29
86.00
TOTAL INCOME
5377.00
4661.91
15462.02
13603.56
17914.63
Total Expenditure
4802.67
4136.10
13884.68
12261.00
16232.57
Decrease in Stock in trade
-327.82
-649.28
-606.38
-584.07
-734.49
Consumption of material
4403.19
4189.34
12422.24
11068.63
14321.04
Staff Cost
178.28
147.50
488.97
425.20
596.86
Other expenditure
549.02
448.54
1579.85
1351.24
2049.16
Interest
139.72
176.56
425.40
372.55
444.10
Depreciation
25.95
20.90
71.40
59.66
78.54
PROFIT BEFORE TAX
408.66
328.35
1080.54
910.35
1159.42
Provision for Tax
30.65
24.63
82.30
71.33
84.36
Provision for Deferred Tax
60.99
4.50
70.65
30.68
55.84
Income Tax for the previous year          
Net Profit
317.02
299.22
927.59
808.34
1019.22
Paid up Equity Share Capital
439.50
439.50
439.50
439.50
439.50
Reserves Excluding Revaluation Reserves    
21.11
18.39
4316.16
EPS - Rs
439.50
6.81
   
2884510
 
NOTES:
1. During the quarter under review, the turnover and the profit before tax of the company has increased by over 15% and 25% respectively as compared to the corresponding quarter of the previous year.

2. The Company has been granted a US Patent for “Controlled Release Macrolide Pharmaceutical Formulations” for one of its products, the market size of which is US $ 300 million.

3. As a part of its expansion plans, the company is setting up a formulation manufacturing facility at Baddi (H.P).

4. The company has received 5 complaints during the quarter under review which were duly redressed to the satisfaction of the shareholders during the same quarter and as such, there were no pending complains as on 31st December, 2003.

5. The Company is exclusively in the Pharmaceutical business segment.

6. The above financial results were taken on record by the Board at its meeting held on 21st January, 2004.
 
On behalf of the Board
 
Sd/-
 
Dated: 21.01.2004
 
(Gopal Munjal)
 
Place: Chandigarh
 
Chairman

Terms of use Copyright © 2005. All rights reserved